Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

cally confined, superficial bladder tumors. In fact intravesical administration exposes the bladder tumor to higher levels of drugs that may prevent tumor cells from becoming invasive and spreading (metastasizing) to other organs. This treatment method is a standard regimen used for many approved chemotherapy drugs to treat superficial bladder cancer.

"I am pleased that we have initiated the studies that explore a novel way of administering LOR-2040 directly to bladder tumors and that we are on schedule to advance LOR-2040 in this indication", said Dr. Aiping Young, President and CEO of Lorus. "Bladder cancer is seventh most common cancer worldwide and is a significant target indication for new therapeutics. Coupled with the high risk of recurrence, even in patients with early stage disease, adding a non-systemic treatment to the currently available treatment options has significant potential."

About LOR-2040

LOR-2040 (formerly GTI-2040) is an RNA-targeted drug candidate specific for the R2 subunit of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. LOR-2040 has demonstrated strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models. LOR-2040 is under study in a multiple Phase I/II clinical program, including an advanced Phase II clinical trial with LOR-2040 and high dose Ara-C (HiDAC) in refractory and relapsed Acute Myeloid Leukemia (AML). The R2 target has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of cancer that are at various stages of development spanning discovery to clinical trials. Lorus' goal is to capitalize on its research, preclin
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... Available in select spas in the ... Fleur’s introduces CC CRÈME Perfect Skin ... makeup, skin care and solar protection in one ... with specific complexion-correcting pigments to instantly blur flaws ... healthy glow. Far more than a concealer, it ...
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... Stem Cell Therapy Better Option for Humans, ... in English,for the first time, The British Institute ... Therapy) training to U.S. medical and,homeopathic practitioners for ... Plant stem cell therapy is more advantageous because,it ...
... Jan. 28 /PRNewswire-FirstCall/ - Quest PharmaTech Inc.,("Quest" ... has signed a,collaborative research agreement with the ... combination therapy for the treatment of lung ... lead oncology product,SL052, with various immunotherapeutic agents. ...
... Phytomedics Inc., a clinical,stage biopharmaceutical company developing novel ... will present at the,Wachovia 2008 Healthcare Conference in ... ET., Among the topics of the presentation ... business developments, including Phase III development,activities related to ...
Cached Biology Technology:Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 3
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Friday, April 20, 2012 Researchers from Cleveland ... greater consumption of sugar-sweetened and low-calorie sodas is associated ... caffeinated or decaffeinated coffee was associated with a lower ... American Journal of Clinical Nutrition is ...
... On the second anniversary of the Deepwater Horizon blowout, ... scientist Samantha Joye is urging the federal government to reassess ... occur in the future. The 22 researchers, whose paper ... , noted that the 2010 Deepwater Horizon oil spill was ...
... 19, 2012 From cognitive neuroscience to theoretical ... Research Fellows from the University of Houston (UH) ... ranging from medicine to energy. Recognizing ... in NSF-supported science, technology, engineering and mathematics disciplines, ...
Cached Biology News:Study finds soda consumption increases overall stroke risk 2Marine scientists urge government to reassess oil spill response 2Marine scientists urge government to reassess oil spill response 3Marine scientists urge government to reassess oil spill response 45 NSF Graduate Research Fellowships awarded to UH students, alumna 25 NSF Graduate Research Fellowships awarded to UH students, alumna 3
... bioassays for interferons are cytopathic effect inhibition ... assays. The neutralization assay measures the ... of the cytokine. Sample types include; tissue ... In these assays, one unit is defined ...
... and Protein G bind specifically to Fc ... and Protein G conjugates are commonly used ... and immunoglobulin subtypes from serum, hybridoma ascites ... fluids. These reagents are also commonly used ...
... complete, flexible system designed specifically for ... is frequently required in biological research. ... miniature Clark-style polarographic electrode. Measuring only ... (3.2 mm), it is ideal for ...
... is a member of the family of human cullin ... to the S. cerevisiae cdc53 gene. Cullin-3 is proposed ... forms a tight complex with cyclin E and targets ... protesomes. Cyclin E is an activator of cdk2, which ...
Biology Products: